{"title":"Immunocore的imtac®平台获得大型制药公司的认可","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1967","DOIUrl":null,"url":null,"abstract":"Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I7.1967\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I7.1967\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact
Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
